Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2023-12-04 Share Issue/Capital Cha…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 November 2023. It details movements in issued shares, share options, warrants, convertibles, and other agreements related to share issuance or repurchase. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital movements and share repurchases. It does not contain financial statements, earnings data, or management discussion. It is a regulatory filing reporting share capital changes and share repurchase activities, fitting the category of Share Issue/Capital Change (SHA). The document length is over 6000 characters, so it is not a mere announcement but a substantive report of share capital movements.
2023-12-04 English
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR NEW INDICATION OF SANBEXIN SUBLINGUAL TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the approval of a clinical trial for a new indication of their product Sanbexin sublingual tablets by the National Medical Products Administration (NMPA) of China. It provides business development information but does not contain financial data, regulatory certifications, voting results, or detailed financial reports. The document is relatively short (4428 characters) and serves as a business update rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement about a clinical trial approval, which is a business update. Given the available categories, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-11-30 English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT WITH CONNECT BIOPHARMA IN RELATION TO IL-4Ra MONOCLONAL ANTIBODY RADEMIKIBART
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited about entering into an exclusive license and collaboration agreement with Connect Biopharma. It details the terms of the agreement, the product involved, and background information about the companies. There is no financial report, no regulatory certification, no voting results, no management changes, no earnings data, and no mention of a report being attached or published. The content is clearly an update on a business development transaction, specifically a licensing and collaboration agreement. This fits best under Capital/Financing Update (CAP) as it relates to a significant business deal involving payments and milestones, which is typical for financing or capital-related announcements. The document length is over 5,000 characters and contains substantive information about the transaction, not just a brief notice or report publication announcement.
2023-11-21 English
CHANGE OF REGISTERED OFFICE ADDRESS
Regulatory Filings Classification · 95% confidence The document is a short announcement from Simcere Pharmaceutical Group Limited regarding a change in the registered office address. It is an official notification about a corporate administrative change, specifically related to the company's registered office location. There is no financial data, no discussion of financial results, no mention of shareholder votes, no legal proceedings, no capital changes, and no detailed report content. The document is brief (1442 characters) and serves as a regulatory announcement. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-17 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details repurchases of shares on various dates, quantities, and prices, confirming compliance with listing rules. The content is focused on reporting share repurchase transactions and capital changes, not on financial results, management changes, or other report types. The document is a regulatory disclosure about share repurchases and capital changes, fitting the definition of a Transaction in Own Shares (POS) filing.
2023-11-16 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details repurchases of shares on various dates, quantities, and prices, confirming compliance with listing rules. The content is focused on reporting share repurchase transactions and changes in issued shares, with no financial statements or earnings data. This matches the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document is over 11,000 characters, so it is not a mere announcement but a detailed report of share repurchases.
2023-11-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.